Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and central nervous system lymphoma: a pilot study

• Conditions: Bloed- en Lymfestelsel aandoeningen: leukemiën; leukaemia and central nervous system lymphoma; 10025320

• Registration Number: NL-OMON47317
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

- All adult patients treated in the Erasmus MC with HD-MTX for a CNS lymphoma or ALL
- Written informed consent

Exclusion Criteria

age < 18 years
no written informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>intracellulair MTX levels (polyglutamates)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>toxicity</p><br>